The lancet oncology
-
The lancet oncology · Apr 2017
Randomized Controlled Trial Multicenter Study Comparative StudyBinimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
There are no established therapies specific for NRAS-mutant melanoma despite the emergence of immunotherapy. We aimed to assess the efficacy and safety of the MEK inhibitor binimetinib versus that of dacarbazine in patients with advanced NRAS-mutant melanoma. ⋯ Array BioPharma and Novartis Pharmaceuticals Corporation.